Your fact-checks will appear here
American pharmaceutical company
No single, broad new drug for general peripheral neuropathy was approved by the FDA in 2024 or 2025 according to the supplied reporting; however, the agency cleared several targeted products relevant ...
Two relevant regulatory moves in 2024–2025 implicate drugs and devices aimed at peripheral neuropathies, but only one — Sangamo’s investigational gene‑regulating candidate ST‑503 — is explicitly docum...
There is no credible evidence that a product called “-cure-claim">Glyco Pizel” (or similarly named supplements like Glycopezil/Glucocil) cures diabetes; available marketing and user-review material co...
There is no credible evidence in the supplied reporting that any product called “Sugar Wise” cures diabetes; mainstream research shows experimental therapies (stem-cell islet transplants, gene therapy...
There is not a single, universally accepted cure for “diabetes” today, because diabetes names multiple diseases with different causes and treatments (type 1 and type 2 being the largest categories) . ...
No single “the neuropathy drug” appears in the supplied reporting as a currently FDA‑approved, broadly labeled treatment for peripheral neuropathy; existing FDA approvals for neuropathic pain focus on...
The short answer: there is no universally accepted, single “” for diabetes today, but major strides—especially for type 1 diabetes (T1D)—make durable remission or functional cures plausible in the com...
Biotech approaches—, beta‑ (including stem‑cell derived and encapsulated transplants), and —are complementary pillars in contemporary research: gene and cell technologies aim to restore or replace ins...
There is no universally accepted, single "" for diabetes today, but multiple promising, disease-modifying approaches are converging—especially for type 1 diabetes () via , gene and immune therapies, a...
A viral “” video typically compresses complex, incremental scientific progress into a single definitive claim; current research shows important advances—especially for —but not a ready‑made, widely av...
OpenSecrets reports that "Pharmaceuticals/Health Products" PACs gave millions to federal candidates in 2023–2024, with industry PAC totals and individual PAC tallies published on its site . However, t...
You asked “Which neuropathy drug are you asking about and what is its generic and brand name?” Available reporting lists multiple drugs, classes and devices under investigation or recently cleared for...
NeuroGold is not mentioned in the available reporting provided for this query; sources instead describe a wave of emerging peripheral neuropathy treatments — including new drugs, spinal-cord and peri...
Multiple academic teams and several companies are now claiming progress toward single‑intervention “cures” for diabetes: Vertex’s stem‑cell infusion Zimislecel produced insulin independence in 10 of 1...
Gene-edited, insulin-producing pancreatic cells have been implanted into a person with type 1 diabetes and produced insulin for months without systemic immunosuppression, marking a medical first and r...
As of mid‑2025, several promising advances toward “functional cures” for type 1 diabetes center on stem‑cell derived islet replacements (zimislecel / Vertex VX‑880 family) with small trials reporting ...
The FDA issued a formal approval on January 30, 2025, for a first-in-class, non-opioid oral analgesic—reported as Journavx (suzetrigine)—for moderate-to-severe acute pain in adults; the agency’s annou...